Literature DB >> 29502125

Exercise Performance of Lowlanders with COPD at 2,590 m: Data from a Randomized Trial.

Michael Furian1,2, Sara E Hartmann3, Tsogyal D Latshang1, Deborah Flueck1, Christian Murer1, Philipp M Scheiwiller1, Batyr Osmonov4, Silvia Ulrich1, Malcolm Kohler1, Marc J Poulin3, Konrad E Bloch1.   

Abstract

BACKGROUND: Effects of hypobaric hypoxia at altitude on exercise performance of lowlanders with chronic obstructive pulmonary disease (COPD) have not been studied in detail.
OBJECTIVES: To quantify changes in exercise performance and associated physiologic responses in lowlanders with COPD travelling to moderate altitude.
METHODS: A total of 31 COPD patients with a median age (quartiles) of 66 years (59; 69) and FEV1 of 56% predicted (49; 69) living below 800 m performed a constant-load bicycle exercise to exhaustion at 60% of the maximal work rate at 490 m (Zurich) and at an identical work rate at 2,590 m (Davos) in randomized order. Pulmonary gas exchange, pulse oximetry (SpO2), cerebral tissue oxygenation (CTO; near-infrared spectroscopy), and middle cerebral artery peak blood flow velocity (MCAv) by Doppler ultrasound during 30 s at end exercise were compared between altitudes.
RESULTS: With ascent from 490 to 2,590 m, the median endurance time (quartiles) was reduced from 500 s (256; 795) to 205 s (139; 297) by a median (95% CI) of 303 s (150-420) (p < 0.001). End exercise SpO2 decreased from 92% (89; 94) to 81% (77; 84) and CTO from 62% (56; 66) to 55% (50; 60); end exercise minute ventilation increased from 40.6 L/min (35.5; 47.8) to 47.2 L/min (39.6; 58.7) (p < 0.05; all comparisons 2,590 vs. 490 m). MCAv increased similarly from rest to end exercise at 490 m (+25% [17; 36]) and at 2,590 m (+21% [14; 30]). However, the ratio of MCAv increase to SpO2 drop during exercise decreased from +6%/% (3; 12) at 490 m to +3%/% (2; 5) at 2,590 m (p < 0.05).
CONCLUSIONS: In lowlanders with COPD travelling to 2,590 m, exercise endurance is reduced by more than half compared to 490 m in association with reductions in systemic and cerebral oxygen availability.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Altitude; Chronic obstructive pulmonary disease; Exercise; Hypobaric hypoxia; Physiology

Mesh:

Year:  2018        PMID: 29502125     DOI: 10.1159/000486450

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  10 in total

Review 1.  Underlying lung disease and exposure to terrestrial moderate and high altitude: personalised risk assessment.

Authors:  Kirsten Holthof; Pierre-Olivier Bridevaux; Isabelle Frésard
Journal:  BMC Pulm Med       Date:  2022-05-09       Impact factor: 3.320

2.  Effect of Nocturnal Oxygen Therapy on Nocturnal Hypoxemia and Sleep Apnea Among Patients With Chronic Obstructive Pulmonary Disease Traveling to 2048 Meters: A Randomized Clinical Trial.

Authors:  Lu Tan; Tsogyal D Latshang; Sayaka S Aeschbacher; Fabienne Huber; Deborah Flueck; Mona Lichtblau; Stefanie Ulrich; Elisabeth D Hasler; Philipp M Scheiwiller; Silvia Ulrich; Konrad E Bloch; Michael Furian
Journal:  JAMA Netw Open       Date:  2020-06-01

3.  Exercise performance and symptoms in lowlanders with COPD ascending to moderate altitude: randomized trial.

Authors:  Michael Furian; Deborah Flueck; Tsogyal D Latshang; Philipp M Scheiwiller; Sebastian Daniel Segitz; Séverine Mueller-Mottet; Christian Murer; Adrian Steiner; Silvia Ulrich; Thomas Rothe; Malcolm Kohler; Konrad E Bloch
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-10-26

4.  Blood pressure response to exposure to moderate altitude in patients with COPD.

Authors:  Esther I Schwarz; Tsogyal D Latshang; Michael Furian; Deborah Flück; Sebastian Segitz; Severine Müller-Mottet; Silvia Ulrich; Konrad E Bloch; Malcolm Kohler
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-03-14

5.  Effect of Dexamethasone on Nocturnal Oxygenation in Lowlanders With Chronic Obstructive Pulmonary Disease Traveling to 3100 Meters: A Randomized Clinical Trial.

Authors:  Michael Furian; Mona Lichtblau; Sayaka S Aeschbacher; Bermet Estebesova; Berik Emilov; Ulan Sheraliev; Nuriddin H Marazhapov; Maamed Mademilov; Batyr Osmonov; Maya Bisang; Stefanie Ulrich; Tsogyal D Latshang; Silvia Ulrich; Talant M Sooronbaev; Konrad E Bloch
Journal:  JAMA Netw Open       Date:  2019-02-01

6.  Effect of Nocturnal Oxygen on Blood Pressure Response to Altitude Exposure in COPD - Data from a Randomized Placebo-Controlled Cross-Over Trial.

Authors:  Martina Meszaros; Tsogyal D Latshang; Sayaka S Aeschbacher; Fabienne Huber; Deborah Flueck; Mona Lichtblau; Stefanie Ulrich; Elisabeth D Hasler; Philipp M Scheiwiller; Lukas Reinhard; Silvia Ulrich; Konrad E Bloch; Michael Furian; Esther I Schwarz
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-12-24

7.  Effect of nocturnal oxygen therapy on exercise performance of COPD patients at 2048 m: data from a randomized clinical trial.

Authors:  Sophia Gutweniger; Tsogyal D Latshang; Sayaka S Aeschbacher; Fabienne Huber; Deborah Flueck; Mona Lichtblau; Stefanie Ulrich; Elisabeth D Hasler; Philipp M Scheiwiller; Silvia Ulrich; Konrad E Bloch; Michael Furian
Journal:  Sci Rep       Date:  2021-10-13       Impact factor: 4.379

8.  Effect of a day-trip to altitude (2500 m) on exercise performance in pulmonary hypertension: randomised crossover trial.

Authors:  Simon R Schneider; Laura C Mayer; Mona Lichtblau; Charlotte Berlier; Esther I Schwarz; Stéphanie Saxer; Lu Tan; Michael Furian; Konrad E Bloch; Silvia Ulrich
Journal:  ERJ Open Res       Date:  2021-10-11

9.  Exercise Capacity, Ventilatory Response, and Gas Exchange in COPD Patients With Mild to Severe Obstruction Residing at High Altitude.

Authors:  Mauricio Gonzalez-Garcia; Margarita Barrero; Dario Maldonado
Journal:  Front Physiol       Date:  2021-06-18       Impact factor: 4.566

10.  Effect of Nocturnal Oxygen Therapy on Daytime Pulmonary Hemodynamics in Patients With Chronic Obstructive Pulmonary Disease Traveling to Altitude: A Randomized Controlled Trial.

Authors:  Mona Lichtblau; Tsogyal D Latshang; Sayaka S Aeschbacher; Fabienne Huber; Philipp M Scheiwiller; Stefanie Ulrich; Simon R Schneider; Elisabeth D Hasler; Michael Furian; Konrad E Bloch; Stéphanie Saxer; Silvia Ulrich
Journal:  Front Physiol       Date:  2021-07-07       Impact factor: 4.566

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.